APGE (Apogee Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


APGE Apogee Therapeutics Inc APGE
12 GF Score
Price $132.69
! 3 Warning Signs
View Full Analysis

What is Apogee Therapeutics EBITDA Margin %?

Apogee Therapeutics APGE -0.14% 12 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates APGE with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Apogee Therapeutics ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apogee Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-82.36 Mil. Apogee Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Apogee Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Apogee Therapeutics  (NAS:APGE) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Apogee Therapeutics EBITDA Margin % Related Terms

Apogee Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Apogee Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apogee Therapeutics EBITDA Margin % Chart

Apogee Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00

Apogee Therapeutics Quarterly Data
Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

APGE vs MIRM, PTCT, RYTM: EBITDA Margin % Comparison

For the Biotechnology subindustry, Apogee Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apogee Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apogee Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Apogee Therapeutics's EBITDA Margin % falls into.


APGE
12GF Score
Apogee Therapeutics Inc APGE
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apogee Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Apogee Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-284.177/0
= %

Apogee Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-82.364/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Apogee Therapeutics (APGE) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apogee Therapeutics and its competitors. According to the industry distribution chart, Apogee Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry.
Is Apogee Therapeutics' EBITDA Margin % too high?
Apogee Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Apogee Therapeutics ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apogee Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Apogee Therapeutics' EBITDA Margin % compare to MIRM and PTCT?
According to the Biotechnology industry distribution chart, Apogee Therapeutics ranks #999999 out of 945 companies for EBITDA Margin %. This places Apogee Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apogee Therapeutics and its competitors. Apogee Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apogee Therapeutics stock overvalued right now?
Apogee Therapeutics (APGE) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Apogee Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apogee Therapeutics (APGE), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apogee Therapeutics Business Description

Address 221 Crescent Street, Building 17, Suite 102b, Waltham, MA, USA, 02453
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
12GF Score

Get the complete analysis for APGE

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$132.69
Price